Refine Search

Search Results -

Terms	Documents
L7 and minimal	3

Database: US Pre-Grant Publication Full-Text Database; US Patents Full-Text Database; US OCR Full-Text Database; EPO Abstracts Database; JPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L12

Refine Search | Recall Text | Clear | Interrupt

Search History

DATE: Saturday, November 10, 2007 Purge Queries | Printable Copy | Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L12	L7 and minimal	3	L12
L11	L7 and (brain or neuron$ or neural$)	5	L11
L10	L7 and IRES	5	L10
DB=PGPB,USPT,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L9	L7 and baron	3	L9
L8	l7 and CMV	5	L8
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L7	(bi-direction$ or bidirection$) near10 promoter$ near25 (retrovir$ or lentivir$) and transgenic	5	L7
L6	(bi-direction$ or bidirection$) near10 promoter$ and transgenic and (retrovir$ or lentivir$)	167	L6
L5	L1 and (brain or neuron$ or neura$)	2	L5
L4	L1 and IRES	0	L4

L3	L1 and ex	0	L3
DB=PGPB,USPT,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L2	L1 and (retrovir$ or lentivir$)	0	L2
L1	7265259 [pn]	2	L1

END OF SEARCH HISTORY

PALM INTRANET

Day : Saturday
Date: 11/10/2007

Time: 17:28:33

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name	**First Name**	
naldini	luigi	Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

PALM INTRANET

Day : Saturday
Date: 11/10/2007

Time: 17:28:33

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name	First Name	
amendola	mario	Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

PALM INTRANET

Day : Saturday
Date: 11/10/2007

Time: 17:28:33

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name	First Name	
vigna	elisa	Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

```
  Set  Items  Description
      ---  -----  -----------
? set hi ;set hi
HILIGHT set on as ''
HILIGHT set on as ''
? begin 5,6,55,154,155,156,312,399,biotech,biosci,biosis
```

```
      Set  Items  Description
      ---  -----  -----------
? s (bidirection? or bi-direction?) (5n) promoter?
           84509  BIDIRECTION?
            1963  BI-DIRECTION?
         1419663  PROMOTER?
      S1    3645  (BIDIRECTION? OR BI-DIRECTION?) (5N) PROMOTER?
? s s1 and (CMV or cytomegalovir?) (5n) minimal
           3645  S1
         116925  CMV
         238719  CYTOMEGALOVIR?
        1114888  MINIMAL
            783  (CMV OR CYTOMEGALOVIR?)(5N)MINIMAL
      S2     12  S1 AND (CMV OR CYTOMEGALOVIR?) (5N) MINIMAL
? rd s2

>>>Duplicate detection is not supported for File 391.

>>>Records from unsupported files will be retained in the RD set.
      S3      5  RD S2  (unique items)
? d s3/3/1-5
      Display 3/3/1     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

18572346   BIOSIS NO.: 200510266846
An establishment of a system for conditional overexpression of genes in
  megakaryocytes and platelets in vivo
AUTHOR: Nguyen Hao G (Reprint); Yu Guangao; Makitalo Maria; Jones Matthew;
  Ravid Katya
AUTHOR ADDRESS: Boston Univ, Sch Med, Boston, MA 02215 USA**USA
JOURNAL: Blood  104 (11, Part 2): p135B NOV 16 2004 2004
CONFERENCE/MEETING: 46th Annual Meeting of the
American-Society-of-Hematology  San Diego, CA, USA  December 04 -07, 2004;
20041204
SPONSOR: Amer Soc Hematol
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

                                - end of record -
?
      Display 3/3/2     (Item 2 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

18489268   BIOSIS NO.: 200510183768
Conditional overexpression of transgenes in megakaryocytes and platelets in
  vivo
AUTHOR: Nguyen Hao G; Yu Guangyao; Makitalo Maria; Yang Dan; Xie Hou-Xiang;
  Jones Matthew R; Ravid Katya (Reprint)
AUTHOR ADDRESS: Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Dept
  Biochem, 715 Albany St,K225, Boston, MA 02118 USA**USA
AUTHOR E-MAIL ADDRESS: ravid@biochem.bumc.bu.edu
JOURNAL: Blood  106 (5): p1559-1564 SEP 1 2005 2005
ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

                                - end of record -
?
```

Display 3/3/3 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

141406766 CA: 141(25)406766e PATENT
Bicistronic lentiviral vectors carrying synthetic bi-directional promoters for gene therapy in human
INVENTOR(AUTHOR): Naldini, Luigi; Amendola, Mario; Vigna, Elisa
LOCATION: Italy
ASSIGNEE: Fondazione Centro San Raffaele del Monte Tabor
PATENT: PCT International ; WO 200494642 A2 DATE: 20041104
APPLICATION: WO 2004IT227 (20040421) *US PV465080 (20030424)
PAGES: 54 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C12N-015/86A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;

-more-

?
Display 3/3/3 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

- end of record -

?
Display 3/3/4 (Item 1 from file: 24)
DIALOG(R)File 24:CSA Life Sciences Abstracts
(c) 2007 CSA. All rts. reserv.

0001541563 IP ACCESSION NO: 3807151
Co-regulation of two gene activities by tetracycline via a bidirectional promoter

Baron, U; Freundlieb, S; Gossen, M; Bujard, H*
Zent. Mol. Biol. Univ. Heidelberg (ZMBH), Im Neuenheimer Feld 282, 69120 Heidelberg, FRG

Nucleic Acids Research, v 23, n 17, p 3605-3606, 1995
ADDL. SOURCE INFO: Nucleic Acids Research [NUCLEIC ACIDS RES.], vol. 23, no. 17, pp. 3605-3606, 1995
PUBLICATION DATE: 1995

DOCUMENT TYPE: Journal Article
RECORD TYPE: Abstract
LANGUAGE: English

-more-

?
Display 3/3/4 (Item 1 from file: 24)
DIALOG(R)File 24:CSA Life Sciences Abstracts
(c) 2007 CSA. All rts. reserv.
ISSN: 0305-1048
FILE SEGMENT: Nucleic Acids Abstracts

- end of record -

?
Display 3/3/5 (Item 1 from file: 144)
DIALOG(R)File 144:Pascal
(c) 2007 INIST/CNRS. All rts. reserv.

17450419 PASCAL No.: 06-0032787
Conditional overexpression of transgenes in megakaryocytes and platelets in vivo. Commentary
NGUYEN Hao G; GUANGYAO YU; MAKITALO Maria; DAN YANG; XIE Hou-Xiang; JONES Matthew R; RAVID Katya; WARE Jerry comment
Department of Biochemistry, Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA, United States; UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES, United States
Journal: Blood, 2005, 106 (5) 1511-1512, 1559-1564 (8 p.)
Language: English

- end of record -

?
? s s1 and CMV and (phosphoglycerate or ubiquitin) and minimal
3645 S1
116925 CMV
29150 PHOSPHOGLYCERATE
156625 UBIQUITIN
1114888 MINIMAL
S4 1 S1 AND CMV AND (PHOSPHOGLYCERATE OR UBIQUITIN) AND MINIMAL
? d s4/9/1
Display 4/9/1 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.
(c) 2007 The Thomson Corp. All rts. reserv.

0410068 DBR Accession No.: 2006-23564 PATENT
New nucleic acid molecule encoding recombinant seven transmembrane G-protein associated receptor, useful for imaging or treating cancer - involving vector-mediated gene transfer and expression in host cell for cancer and leukemia therapy and gene therapy
AUTHOR: KUNDRA V; FANG B; JI L X; YANG D
PATENT ASSIGNEE: UNIV TEXAS SYSTEM 2006
PATENT NUMBER: WO 200699019 PATENT DATE: 20060921 WPI ACCESSION NO.: 2006-648989 (200667)
PRIORITY APPLIC. NO.: US 659844 APPLIC. DATE: 20050309
NATIONAL APPLIC. NO.: WO 2006US8374 APPLIC. DATE: 20060309
LANGUAGE: English
ABSTRACT: DERWENT ABSTRACT: NOVELTY - A nucleic acid molecule comprising a coding region encoding a recombinant seven transmembrane G-protein associated receptor (GPCR) amino acid sequence, the coding region operatively linked to a tissue-selective promoter sequence, is new.

-more-

?
Display 4/9/1 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.
(c) 2007 The Thomson Corp. All rts. reserv.
DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method of imaging or treating cells in a subject. BIOTECHNOLOGY - Preferred Nucleic Acid: The recombinant GPCR has a C-terminal deletion, has an altered internalization, is defective in intracellular signaling, or their combination. The GPCR is an acetylcholine receptor: M1, M2, M3, M4, or M5; adenosine receptor: A1; A2A; A2B; or A3; adrenoceptors: alpha1A, alpha1B, alpha1D, alpha2A, alpha2B, alpha2C beta1, beta2, or beta3; angiotensin receptors: AT1, or AT2; bombesin receptors: BB1, BB2, or BB3; bradykinin receptors: B1, B2, calcitonin, Ainilin, CGRP,

or adrenomedullin receptors; cannabinoid receptors: CB1, or CB2; chemokine receptors: CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CX3CR1, or XCR1; chemotactic receptors: C3a, C5a, or fMLP; cholecystokinin and gastrin receptors: CCK1, or CCK2; corticotropin-releasing factor receptors: CRF1, or CRF2; dopamine receptors: D1, D2, D3, D4, or D5; endothelin receptors: ET(A) or ET(B); galanin receptors: GAL1, GAL2, or GAL3; glutamate receptors: mgl1, mgl2, mgl3, mgl4, mgl5, mgl6o, mgl7, or

-more-

?

Display 4/9/1 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.

mgl8; glycoprotein hormone receptors: FSH, LSH, or TSH; histamine receptors: H1, H2, H3, or H4; 5-HT receptors: 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1B, 5-HT1F, 5HT2A, 5-HT2F, 5-HT2C, 5-HT3, 5-HT4, 5-HT5A, 5-HT5B, 5-HT6, or 5-HT7; leukotriene receptors: BLT, CysLT1, or CysLT2; lysophospholipid receptors: edg1, edg2, edg3, or edg4; melanocortin receptors: MC1; MC2; MC3; MC4, or MC5; melatonin receptors: MT1, MT2, or MT3; neuropeptide Y receptors: Y1, Y2, Y4, Y5, or Y6; neurotension receptors: NTS1, or NTS2; opioids: DOP, KOP, MOP, or NOP; P2Y receptors: P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, or P2Y12; peroxisome proliferators: PPAR-alpha, PPAR-beta, or PPAR-gamma; prostanoid receptors: DP, FP, IP, TP, EP1, EP2, EP3, or EP4; protease-activated receptors: PAR1, PAR2, PAR3, or PAR4; Somatostatin receptors: SSTR1, SSTR2, SSTR2A, SSTR3, SSTR4, or SSTR5; tachyldnin receptors: NK1, NK2, or NK3; thyrotropin-releasing hormone receptors: TRH1, or TRH2; urotensin-II receptor; vasoactivate intestinal peptide or pituitary adenylate cyclase activating peptide receptors: VPAC1, VPAC2, or PAC1; or vasopressin or oxytocin receptors: V1a, V1b, V2, or OT. The GPCR is

-more-

?

Display 4/9/1 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.

a somatostatin receptor, where the somatostatin receptor is a somatostatin receptor type 2A (SSTR2A), where the SSTR2A is signaling defective, has altered internalization, or their combination, where the SSTR2A is truncated, and where the SSTR2A is truncated carboxy terminal to amino acid 314. The promoter sequence is a telomerase promoter, a human telomerase RNA (hTR) promoter, human telomerase reverse transcriptase promoter (hTERT) promoter, hTR operatively coupled to an amplification mechanism, or hTERT operatively coupled to an amplification mechanism. The tissue-selective promoter or amplified tissue specific promoter is active in normal and/or diseased heart, lung, esophagus, muscle, intestine, breast, prostate, stomach, bladder, liver, spleen, pancreas, kidney, neurons, myocytes, leukocytes, immortalized cells, neoplastic cells, tumor cells, cancer cells, duodenum, jejunum, ileum, cecum, colon, rectum, salivary glands, gall bladder, urinary bladder, trachea, larynx, pharynx, aorta, arteries, capillaries, veins, thymus, lymph nodes, bone marrow, pituitary gland, thyroid gland, parathyroid glands, adrenal glands, brain, cerebrum,

-more-

?

Display 4/9/1 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.

cerebellum, medulla, pons, spinal cord, nerves, skeletal muscle, smooth muscle, bone, testes, epidymidis, prostate, seminal vesicles, penis, ovaries, uterus, mammary glands, vagina, skin, eyes, optic nerve, a promoter active in tissues derived from the same embryonic origin or

one or more tissues effected by the same or similar disease, where the tissue selective promoter is active in a neoplastic cell, a tumor, or a cancer cell, e.g. a breast cancer cell, a lung cancer cell, a prostate cancer cell, an ovarian cancer cell, a brain cancer cell, a liver cancer cell, a cervical cancer cell, a colon cancer cell, a renal cancer cell, a skin cancer cell, a head and neck cancer cell, a bone cancer cell, an esophageal cancer cell, a bladder cancer cell, a uterine cancer cell, a lymphatic cancer cell, a stomach cancer cell, a pancreatic cancer cell, a testicular cancer cell, a lymphoma cell, or a leukemic cell. The promoter sequence is an hTR promoter sequence, hTERT promoter sequence, CEA promoter sequence, a PSA promoter sequence, a probasin promoter sequence, a ARR2PB promoter sequence, AFP promoter sequence, MUC-I, MUC-4, mucin-like glycoprotein, C-erbB2/neu oncogene,

-more-

?

Display 4/9/1 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.
(c) 2007 The Thomson Corp. All rts. reserv.

Cyclooxygenase, E2F transcription factor 1, tyrosinase related protein, tyrosinase, or survivin, Tcfl-alpha, Ras, Raf, cyclin E, Cdc25A, HKII, KRT19, TFFl, SELlL, or an CEL. The promoter sequence is an hTERT promoter sequence that is functional in a cancer cell. The promoter sequence is an immunoglobulin heavy chain promoter sequence, an immunoglobulin light chain promoter sequence, a T-cell receptor promoter sequence, an HLA DQ a promoter sequence, an HLA DQ beta promoter sequence, a beta-interferon promoter sequence, an interleukin-2 promoter sequence, an interleukin-2 receptor promoter sequence, an MHC Class II 5 promoter sequence, an MHC Class II HLA-Dra promoter sequence, a beta-actin promoter sequence, a muscle creatine kinase (MCK) promoter sequence, a prealbumin (transthyretin) promoter sequence, an elastase I promoter sequence, a metallothionein (MTII) promoter sequence, a collagenase promoter sequence, an albumin promoter sequence, an alpha-fetoprotein promoter sequence, a gamma-globin promoter sequence, a beta-globin promoter sequence, a c-fos promoter sequence, a c-HA-ras promoter sequence, an insulin promoter sequence, a

-more-

?

Display 4/9/1 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.
(c) 2007 The Thomson Corp. All rts. reserv.

neural cell adhesion molecule (NCAM) promoter sequence, an alpha-1-antitrypsin promoter sequence, an H2B (TH2B) histone promoter sequence, a type I collagen promoter sequence, a GRP94 promoter sequence, a GRP78 promoter sequence, an other glucose-regulated protein promoter sequence, a growth hormone promoter sequence, a human serum amyloid A (SAA) promoter sequence, a troponin I (TN I) promoter sequence, a platelet-derived growth factor (PDGF) promoter sequence, a Duchenne Muscular Dystrophy promoter sequence, an SV40 promoter sequence, a polyoma promoter sequence, a retrovirus promoter sequence, a papilloma virus promoter sequence, a Hepatitis B virus promoter sequence, a Human Immunodeficiency Virus promoter sequence, a Cytomegalovirus promoter sequence, a Gibbon Ape Leukemia Virus promoter sequence, a human LIMK2 gene promoter sequence, a somatostatin receptor promoter sequence, a murine epididymal retinoic acid-binding gene promoter sequence, a human CD4 promoter sequence, a mouse alpha2 (XI) collagen promoter sequence, a D1A dopamine receptor promoter sequence, an insulin-like growth factor II promoter sequence, human platelet

-more-

?

Display 4/9/1 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.

(c) 2007 The Thomson Corp. All rts. reserv.
endothelial cell adhesion molecule-1 promoter sequence, a human alpha-lactalbumin promoter sequence, a 7SL promoter sequence, a human Y promoter sequence, a human MRP-7-2 promoter sequence, a 5S ribosomal promoter sequence, alpha fetoprotein, monocyte receptor for bacterial LPS, leukosialin, Sialophorin, leukocyte common antigen, Macrosialin or human analog of macrosialin, Desmin, Elastase, Elastase I, Endoglin, fibronectin, vascular endothelail growth factor (VEGF) receptors, glial fibrillary acidic protein, intercellular adhesion molecule 2, interferon beta, myoglobin, osteocalcin 2, prostate specific antigen, prostate specific membrane antigen, surfactant protein B, Synapsin, tyrosinase related protein, tyrosinase, or a functional hybrid, functional portion, or a combination of any of tissue/disease /lineage specific promoter sequences. The tissue-selective promoter sequence is operatively coupled to a core promoter sequence, where the core promoter sequence is derived from a constitutive promoter such as ubiquitin promoter, an actin promoter, an elongation factor 1 alpha, an early growth factor response 1, an eukaryotic initiation

-more-

?
Display 4/9/1 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.
(c) 2007 The Thomson Corp. All rts. reserv.
factor 4Al, a ferritin heavy chain, a ferritin light chain, a glyceraldehyde 3-phosphate dehydrogenase, a glucose-regulated protein 78, a glucose-regulated protein 94, a heat shock protein 70, a heat shock protein 90, a beta-kinesin, a phosphoglycerate kinase, an ubiquitin B, a beta-actin or a minimal viral promoter sequence. The ***minimal*** viral promoter sequence is a RNA virus promoter, DNA virus promoter, adenoviral promoter sequence, a baculoviral promoter sequence, a CMV promoter sequence, a parvovirus promoter sequence, a herpesvirus promoter sequence, a poxvirus promoter sequence, an adeno-associated virus promoter sequence, a semiwild forest virus promoter sequence, an SV40 promoter sequence, a vaccinia virus promoter sequence, a lentivirus promoter, or a retrovirus promoter sequence. The ***minimal*** viral promoter sequence is a mini-CMV promoter sequence, where the tissue selective promoter is the hTERT promoter, and where the hTERT promoter is operatively coupled to a first reporter. The nucleic acid further comprises a second coding sequence where the second coding sequence

-more-

?
Display 4/9/1 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.
(c) 2007 The Thomson Corp. All rts. reserv.
encodes a therapeutic, a selectable marker, a recombinant transactivator, or a second imaging gene (reporter). The nucleic acid comprises a first reporter is SSTR2 and a second reporter that is green fluorescent protein (GFP). The nucleic acid further comprises a second coding sequence operatively coupled to a second tissue-selective promoter sequence, or an amplified tissue specific promoter or a non-selective promoter such as a ***CMV*** promoter. The second coding sequence encodes a therapeutic, a selectable marker, a recombinant transactivator, or a second imaging gene (reporter), where the therapeutic is a tumor suppressor, an inducer apoptosis, an enzyme, a structural protein, a receptor, an antibody, an antibody fragment, a siRNA, a hormone, a paracrine factor, or an immunostimulant, and where the tumor suppressor is FUS1. The selectable marker is a drug selection marker, an enzyme, a structural protein, a receptor, a paracrine factor, an immunologic marker, or a fluorescent protein. The nucleic acid further comprises a second coding sequence, where the second coding sequence and the nucleic acid encoding the reporter are

-more-

?
Display 4/9/1 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.
(c) 2007 The Thomson Corp. All rts. reserv.

operatively linked. The nucleic acid further comprises a second coding sequence, where the second coding sequence and the nucleic acid encoding the recombinant GPCR amino acid sequence are operatively coupled to a ***bidirectional*** ***promoter*** . The nucleic acid further comprises a second coding sequence, where the second coding sequence and the nucleic acid encoding the recombinant seven transmembrane G-protein associated receptor amino acid sequence are separated by an 1RES. The nucleic acid further comprises a protein tag fused to the N-terminal end or C-terminal end of the GPCR amino acid sequence, where the protein tag has enzymatic activity, and where the protein tag is hemagglutinin A, beta-galactosidase, thymidine kinase, transferin, myc-tag, VP16, (His)e-tag, FLAG, or chloramphenicol acetyl transferase. A nucleic acid comprises a nucleic acid sequence encoding a reporter that is detectable in a subject by non-invasive methods operatively coupled to a promoter sequence that binds a recombinant transactivator. The recombinant transactivator is Gal4VP16. The nucleic acid sequence further comprises a third coding sequence operatively

-more-

? s s1 and IRES
3645 S1
15888 IRES
S5 6 S1 AND IRES
? d s5/3/1-6
Display 5/3/1 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

143280128 CA: 143(16)280128u JOURNAL
Construction and characterization of multiple human colon cancer cell lines for inducibly regulated gene expression
AUTHOR(S): Welman, Arkadiusz; Cawthorne, Christopher; Barraclough, Jane; Smith, Nigel; Griffiths, Gareth J.; Cowen, Rachel L.; Williams, Judith C.; Stratford, Ian J.; Dive, Caroline
LOCATION: Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Cancer Research UK, Manchester, UK, M20 4BX
JOURNAL: J. Cell. Biochem. (Journal of Cellular Biochemistry) DATE: 2005
VOLUME: 94 NUMBER: 6 PAGES: 1148-1162 CODEN: JCEBD5 ISSN: 0730-2312
LANGUAGE: English PUBLISHER: Wiley-Liss, Inc.

- end of record -

?
Display 5/3/2 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

142255452 CA: 142(14)255452s JOURNAL
Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters
AUTHOR(S): Amendola, Mario; Venneri, Mary Anna; Biffi, Alessandra; Vigna, Elisa; Naldini, Luigi
LOCATION: San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), San Raffaele Scientific Institute, 20132, Milan, Italy
JOURNAL: Nat. Biotechnol. (Nature Biotechnology) DATE: 2005 VOLUME: 23
NUMBER: 1 PAGES: 108-116 CODEN: NABIF9 ISSN: 1087-0156 LANGUAGE: English PUBLISHER: Nature Publishing Group

- end of record -

?
Display 5/3/3 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

141406766 CA: 141(25)406766e PATENT
Bicistronic lentiviral vectors carrying synthetic bi-directional promoters for gene therapy in human
INVENTOR(AUTHOR): Naldini, Luigi; Amendola, Mario; Vigna, Elisa
LOCATION: Italy
ASSIGNEE: Fondazione Centro San Raffaele del Monte Tabor
PATENT: PCT International ; WO 200494642 A2 DATE: 20041104
APPLICATION: WO 2004IT227 (20040421) *US PV465080 (20030424)
PAGES: 54 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C12N-015/86A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;

-more-

?
Display 5/3/3 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ ; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

- end of record -

?
Display 5/3/4 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

138132167 CA: 138(10)132167n PATENT
Retrovirus vector for reversible gene integration into mammalian cells for gene therapy
INVENTOR(AUTHOR): Itoh, Akira; Hanazono, Yutaka; Ozawa, Keiya
LOCATION: Japan,
PATENT: U.S. Pat. Appl. Publ. ; US 20030022375 A1 DATE: 20030130
APPLICATION: US 188075 (20020703) *JP 2001205236 (20010705)
PAGES: 21 pp. CODEN: USXXCO LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 435455000; C12N-015/85A; C12N-005/06B

- end of record -

?
Display 5/3/5 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci
(c) 2007 The Thomson Corp. All rts. reserv.

14547360 Genuine Article#: 984NP Number References: 25
Title: A series of bidirectional tetracycline-inducible promoters provides coordinated protein expression
Author(s): Sammarco MC; Grabczyk E (REPRINT)
Corporate Source: Louisiana State Univ,Hlth Sci Ctr, Dept Genet,New Orleans//LA/70112 (REPRINT); Louisiana State Univ,Hlth Sci Ctr, Dept Genet,New Orleans//LA/70112; Louisiana State Univ,Hlth Sci Ctr, Dept Pathol,New Orleans//LA/70112(egrabc@lsuhsc.edu)

Journal: ANALYTICAL BIOCHEMISTRY, 2005, V346, N2 (NOV 15), P210-216
ISSN: 0003-2697 Publication date: 20051115
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCE, 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)

- end of record -

?
Display 5/3/6 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

12156538 EMBASE No: 2003266158
Development of Nurr1 stable cell lines for the identification of downstream targets
Luo Y.; Henricksen L.A.; Maguire-Zeiss K.A.; Federoff H.J.
Dr. H.J. Federoff, University of Rochester Sch. of Medicine, 601 Elmwood Ave., Rochester, NY 14642 United States
AUTHOR EMAIL: howard federoff@urmc.rochester.edu
Annals of the New York Academy of Sciences (ANN. NEW YORK ACAD. SCI.) (United States) 2003, 991/- (354-358)
CODEN: ANYAA ISSN: 0077-8923
DOCUMENT TYPE: Journal ; Conference Paper
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 1

- end of record -

? s s1 and (retrovir? or lentivir?) (5n) vector?
3645 S1
717574 RETROVIR?
114313 LENTIVIR?
2379630 VECTOR?
85840 (RETROVIR? OR LENTIVIR?)(5N)VECTOR?
S6 29 S1 AND (RETROVIR? OR LENTIVIR?) (5N) VECTOR?
? s s6 and minimal
29 S6
1114888 MINIMAL
S7 2 S6 AND MINIMAL
? d s7/3/1-2
Display 7/3/1 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

141406766 CA: 141(25)406766e PATENT
Bicistronic lentiviral vectors carrying synthetic bi-directional promoters for gene therapy in human
INVENTOR(AUTHOR): Naldini, Luigi; Amendola, Mario; Vigna, Elisa
LOCATION: Italy
ASSIGNEE: Fondazione Centro San Raffaele del Monte Tabor
PATENT: PCT International ; WO 200494642 A2 DATE: 20041104
APPLICATION: WO 2004IT227 (20040421) *US PV465080 (20030424)
PAGES: 54 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C12N-015/86A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;

-more-

?
Display 7/3/1 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ ; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

- end of record -

?

Display 7/3/2 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.

0368894 DBR Accession Number: 2005-14600 PATENT
New bidirectional promoter comprises control elements for transcription of short RNA sequences, useful for expressing short RNA sequences from a single promoter - method of virus infection gene therapy involving the use of RNA interference for virus genome gene expression suppression
AUTHOR: LOU K
PATENT ASSIGNEE: WELGEN INC; FRICK G P; DU L 2005
PATENT NUMBER: WO 200535718 PATENT DATE: 20050421 WPI ACCESSION NO.: 2005-296272 (200530)
PRIORITY APPLIC. NO.: US 508821 APPLIC. DATE: 20041002
NATIONAL APPLIC. NO.: WO 2004US32158 APPLIC. DATE: 20041002
LANGUAGE: English

- end of record -

? e au=naldini, luigi

Ref	Items	Index-term
E1	7	AU=NALDINI, L*
E2	18	AU=NALDINI, LUCIANA
E3	145	*AU=NALDINI, LUIGI
E4	1	AU=NALDINI, LUIGI T
E5	4	AU=NALDINI, M.
E6	2	AU=NALDINI, N.
E7	1	AU=NALDINI, ROSELLA
E8	5	AU=NALDINI, S.
E9	1	AU=NALDINILONGO B
E10	2	AU=NALDJIAN S
E11	2	AU=NALDJIAN SANTIAGO
E12	2	AU=NALDMANN, H.

Enter P or PAGE for more

? e au=naldini luigi

Ref	Items	Index-term
E1	4	AU=NALDINI LONGO, B.
E2	2	AU=NALDINI LUCIANA
E3	313	*AU=NALDINI LUIGI
E4	3	AU=NALDINI M
E5	2	AU=NALDINI MARCO
E6	2	AU=NALDINI R
E7	1	AU=NALDINI S
E8	5	AU=NALDINI S.
E9	13	AU=NALDINI, A
E10	56	AU=NALDINI, A.
E11	113	AU=NALDINI, ANTONELLA
E12	1	AU=NALDINI, B

Enter P or PAGE for more

? e au=amendola, mario

```
Ref    Items  Index-term
E1         7 *AU=AMENDOLA, MARIO
E2         1  AU=AMENDOLA, MC
E3         3  AU=AMENDOLA, MICHAEL
E4         1  AU=AMENDOLA, MP
E5         2  AU=AMENDOLA, N.
E6         2  AU=AMENDOLA, P
E7         9  AU=AMENDOLA, PAOLA
E8         1  AU=AMENDOLA, PLINIO
E9         8  AU=AMENDOLA, R
E10       20  AU=AMENDOLA, R.
E11        1  AU=AMENDOLA, R. C.
E12        1  AU=AMENDOLA, R. D.

          Enter P or PAGE for more
? e au=amendola mario

Ref    Items  Index-term
E1         7 *AU=AMENDOLA MARIO
E2         4  AU=AMENDOLA MARY GRACE
E3         1  AU=AMENDOLA MASSIOTTI, R.
E4         3  AU=AMENDOLA MC
E5         1  AU=AMENDOLA ME
E6         1  AU=AMENDOLA MG
E7         5  AU=AMENDOLA MICHAEL
E8         1  AU=AMENDOLA MP
E9         6  AU=AMENDOLA N
E10        8  AU=AMENDOLA N.
E11       12  AU=AMENDOLA NED
E12        1  AU=AMENDOLA O

          Enter P or PAGE for more
? e au=vigna, elisa

Ref    Items  Index-term
E1        12  AU=VIGNA, E
E2        14  AU=VIGNA, E.
E3        28 *AU=VIGNA, ELISA
E4         8  AU=VIGNA, ENRICO
E5         2  AU=VIGNA, ERNESTO
E6         8  AU=VIGNA, F.
E7         1  AU=VIGNA, F.E.
E8       113  AU=VIGNA, G.
E9        14  AU=VIGNA, G. B.
E10        1  AU=VIGNA, G. L.
E11        1  AU=VIGNA, G.B.
E12        1  AU=VIGNA, GERALD S.

          Enter P or PAGE for more
? e au=vigna elisa

Ref    Items  Index-term
E1       123  AU=VIGNA E
E2        48  AU=VIGNA E.
E3        28 *AU=VIGNA ELISA
E4        21  AU=VIGNA ERNESTO
E5         9  AU=VIGNA F
E6         4  AU=VIGNA F.
E7         5  AU=VIGNA F.E.
E8         1  AU=VIGNA FE
E9         1  AU=VIGNA FILHO E D
E10        1  AU=VIGNA FILHO, E.
E11       11  AU=VIGNA FRANCO
E12        4  AU=VIGNA FRANCO E
```

Enter P or PAGE for more
? s e1
S8 123 AU='VIGNA E'
? s s8 and bidirection?
123 S8
84509 BIDIRECTION?
S9 2 S8 AND BIDIRECTION?
? d s9/3/1-2
Display 9/3/1 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

13504899 Genuine Article#: 885ZK No. References: 32
Title: Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters
Author(s): Amendola M; Venneri MA; Biffi A; Vigna E; Naldini L (REPRINT)
Corporate Source: San Raffaele Telethon Inst Gene Therapy HSR TIGET,Via Olgettina 58/I-20132 Milan//Italy/ (REPRINT); San Raffaele Telethon Inst Gene Therapy HSR TIGET,I-20132 Milan//Italy/; Vita Salute San Raffaele Univ,San Raffaele Sci Inst,I-20132 Milan//Italy/; Univ Turin,Sch Med, Inst Canc Res & Treatment,I-10060 Turin//Italy/(naldini.luigi@hsr.it)
Journal: NATURE BIOTECHNOLOGY, 2005, V23, N1 (JAN), P108-116
ISSN: 1087-0156 Publication date: 20050100
Publisher: NATURE PUBLISHING GROUP, 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA
Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)

- end of record -

?
Display 9/3/2 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.

0360794 DBR Accession No.: 2005-06498
Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters - gene transfer and tissue-specific gene expression using a lenti virus expression vector useful for a gene therapy application
AUTHOR: AMENDOLA M; VENNERI MA; BIFFI A; VIGNA E; NALDINI L
CORPORATE AFFILIATE: San Raffaele Telethon Inst Gene Therapy HSR TIGET Vita Salute San Raffaele Univ; Univ Turin
CORPORATE SOURCE: Naldini L, San Raffaele Telethon Inst Gene Therapy HSR TIGET, Via Olgettina 58, I-20132 Milan, Italy
JOURNAL: NATURE BIOTECHNOLOGY (23, 1, 108-116) 2005
ISSN: 1087-0156
LANGUAGE: English

- end of record -

?